Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6642MR)

This product GTTS-WQ6642MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5187MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ3759MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ7672MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ8788MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ6809MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ10544MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12449MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ11600MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW